local GMP frameworks such as India’s Schedule M or country-specific adaptations of PIC/S

Not always harmonized with WHO or ICH guidelines

Inspections may focus more on documentation and basic infrastructure

In some cases, enforcement and oversight resources may be limited

3. Scope of Evaluation:

WHO PQP GMP

• Comprehensive, includes production, packaging, QC, validation, QMS, and post-marketing practices
• Focused on facilities manufacturing products for HIV, TB, malaria, reproductive health, etc.
• Assesses SOPs, batch records, analytical methods, and CAPA systems

Local GMP

• Often limited to regulatory checklists and routine manufacturing protocols
• Focus may be more on infrastructure and less on risk management or global harmonization
• May not evaluate full product lifecycle or supply chain management

4. Recognition and Strategic Use:

WHO PQP GMP

• Mandatory for participation in Global Fund, UNICEF, UNDP, and GAVI procurements
• Serves as a gateway to Collaborative Registration Procedure (CRP) in over 30 countries
• Boosts credibility with Stringent Regulatory Authorities (SRAs)

Local GMP

• Required for national marketing authorization and manufacturing license
• May be accepted regionally (e.g., SADC, ASEAN, EU mutual recognition)
• Generally not recognized for international tenders or global procurement

5. Inspection Process and Timeline:

WHO PQP GMP

• Risk-based inspection scheduling depending on product category and prior history
• Joint inspections with NRAs and external experts
• Typically lasts 4–5 days with in-depth reviews of critical systems
• CAPA responses expected within 60 days post-inspection

Local GMP

• Scheduled periodically or upon license renewal/application
• Duration and depth may vary significantly
• CAPA timelines can range from 30 to 90 days depending on country

6. Documentation and Evidence Requirements:

• WHO PQP audits require complete traceability in data, validated cleaning, and robust quality metrics
• Emphasis on data integrity, risk-based control strategies, and continual improvement
• Local inspections may require a narrower scope of documentation
• Global procurement organizations may reject products with local GMP alone

7. Post-Certification Monitoring:

WHO PQP

• Subject to reinspection every 3–5 years
• Annual Product Review (APR) submissions required
• Variations must be reported and approved through WHO’s variation classification system

Local GMP

• Re-certification timelines and requirements depend on local policy
• Post-approval changes may not require prior approval in some regions
• Enforcement may vary based on the strength of the NRA

Strategic Implications for Manufacturers:

• WHO PQP GMP certification is vital for manufacturers aiming for international supply
• It improves global recognition, reduces inspection duplication, and supports reliance models
• Local GMP is necessary for national operations but insufficient for global competitiveness
• Dual certification (local + WHO PQP) enhances both domestic and international market access

Conclusion:

While local GMP certification enables domestic legitimacy, WHO PQP GMP certification is the passport to international quality recognition and procurement eligibility. Understanding their differences in scope, rigor, and strategic impact helps manufacturers align with global health goals while meeting country-specific compliance requirements. For forward-looking pharmaceutical companies, integrating both certifications into a unified quality strategy is not just regulatory—it’s transformational.